Galapagos CSO hits the exit as the biotech looks to pick up the pieces after FDA’s filgotinib rejection

Months after Galapagos cut away broad swaths of its pipeline following a rejection for Gilead-partnered rheumatoid arthritis drug filgotinib, the biotech will now say goodbye to its longtime chief scientific officer as it considers its options moving ahead.

Walid Abi-Saab

Piet Wigerinck will step...

Click to view original post